GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more
GeneReach Biotechnology - Asset Resilience Ratio
GeneReach Biotechnology (4171) has an Asset Resilience Ratio of 33.33% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how GeneReach Biotechnology's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down GeneReach Biotechnology's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$292.47 Million | 33.33% |
| Total Liquid Assets | NT$292.47 Million | 33.33% |
Asset Resilience Insights
- Very High Liquidity: GeneReach Biotechnology maintains exceptional liquid asset reserves at 33.33% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
GeneReach Biotechnology Industry Peers by Asset Resilience Ratio
Compare GeneReach Biotechnology's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for GeneReach Biotechnology (2018–2024)
The table below shows the annual Asset Resilience Ratio data for GeneReach Biotechnology.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.90% | NT$393.49 Million | NT$1.07 Billion | +10.11pp |
| 2023-12-31 | 26.79% | NT$315.10 Million | NT$1.18 Billion | +25.84pp |
| 2022-12-31 | 0.95% | NT$15.36 Million | NT$1.62 Billion | +0.13pp |
| 2021-12-31 | 0.82% | NT$13.84 Million | NT$1.68 Billion | -2.62pp |
| 2020-12-31 | 3.44% | NT$42.72 Million | NT$1.24 Billion | -30.26pp |
| 2018-12-31 | 33.70% | NT$233.82 Million | NT$693.83 Million | -- |